This pulmonary LNP formulation is delivered by inhalation, uses multiple lipids, and may be able to target specific areas of the lung. It is currently being studied in a Phase 1 trial from Vertex, evaluating the safety, and tolerability and efficacy of VX-522 in participants 18 years of age...
研发团队以多价新冠mRNA疫苗为例，对LQ-3 iPLX作为疫苗平台的潜力进行评估，LQ-3 iPLX和SM-102 LNP...
to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant
Propionic acidemia (PA) (mRNA-3927):ThePhase 1/2 Paramount studyof mRNA-3927 is ongoing. mRNA-3927 uses the same LNP formulation as mRNA-1944. This is the Company’s first development candidate in its systemic intracellular therapeutics modality to enter the clinic. Mod...
mRNA-1345是一种编码RSV融合前F糖蛋白的单价mRNA疫苗,与融合后状态相比,可引起更高的中和抗体反应。这一疫苗使用与Moderna的新冠疫苗相同的脂质纳米颗粒(LNP)装载,包含优化的蛋白和密码子序列。除适用于老年人外,mRNA-1345还在进行一项用于儿童的1期临床试验。
Over the 10 years since our inception, we have sustained large investments in platform science, including both mRNA and Lipid Nanoparticle (LNP) formulation. And we have established a large intellectual property (IP) portfolio that will protect and enhance our ability to continue to invest in inno...
forward-looking statements. These risks, uncertainties and other factors include, among others: whether the Phase 1 results for mRNA-1944 will be predictive of any future clinical studies for mRNA-1944 or other development candidates with the same ...